ARYA Sciences Acquisition Corp III: directors' dealings · United States · SEC (Form 4)

About ARYA Sciences Acquisition Corp III

ARYA Sciences Acquisition Corp III is, in origin, a U.S.-listed SPAC that traded on the NASDAQ market in the United States. It was formed as a blank-check acquisition vehicle sponsored by Perceptive Advisors, with the mandate to identify and merge with an attractive company in the life sciences or healthcare innovation space. As such, ARYA III did not operate as a conventional industrial business with its own product portfolio; instead, its core business model was to raise capital in the public markets, hold proceeds in trust, and execute a business combination with a target company viewed as strategically compelling. Historically, the most important corporate event for ARYA III was its announced merger with Nautilus Biotechnology in 2021. That transaction effectively converted the SPAC shell into a public listing vehicle for a next-generation proteomics company. Nautilus is focused on single-molecule protein analysis and on technologies intended to improve human proteome measurement, which places the business in a highly innovative and potentially disruptive segment of biotechnology tools and precision medicine research. In practical terms, the “business lines” of ARYA III before the merger were those of a SPAC sponsor platform; after the combination, the economic profile tied to the former ARYA III vehicle became that of Nautilus Biotechnology. Nautilus’ headquarters are in Seattle, Washington, United States, and the company also conducts scientific research and development from its San Carlos, California location. For investors, that distinction matters: ARYA III is best understood as the historic SPAC structure, while the operating story is centered on the merged life sciences company. From a competitive standpoint, the investment case is tied to a still-emerging proteomics market, where single-molecule measurement platforms may unlock better biomarker discovery, drug development insights, and, over time, broader clinical utility. The company’s key product/service area is its proteomics platform rather than a diversified commercial portfolio. Its geographic footprint is primarily U.S.-based, with operations anchored in the West Coast biotech ecosystem. Recent milestones have included the completion of the business combination and the transition to a NASDAQ-listed public company under the Nautilus Biotechnology name and ticker. For French-speaking investors, the stock should therefore be viewed as a science-driven growth story with significant execution risk, dependent on technological validation, commercialization progress, and the pace of adoption in advanced life sciences research.